Economic evaluations of differentiated service delivery should include savings and ancillary benefits, not only health system costs We write in reference to the study by Nichols et al.[1] that evaluated costs and outcomes of community-based differentiated service delivery (DSD) models for HIV treatment in Zambia. The authors compared conventional, facility-based care to mobile antiretroviral therapy (ART), community adherence groups (CAGs), urban adherence groups (UAGs), and home delivery of ART under the Community HIV Epidemic Control (CHEC) model. The authors found that conventional care was least expensive in terms of direct clinical service and medication costs, whereas mobile ART, CAGs, UAGs, and CHEC were more expensive, in that order.We appreciate this detailed costing analysis of DSD models in Zambia. At the University of Maryland Baltimore, we have nearly two decades of experience in the provision of medical/technical service delivery in Zambia [2]. Based on community-based approaches demonstrated to improve HIV case-finding and linkage [3], provide high-quality care [4], and improve retention in adult ART programs [5], we developed and implemented the CHEC model [6], which provides home delivery of ART and was one of the models evaluated in this analysis. CHEC was primarily implemented in the PEPFAR/CDC-funded Stop Mother and Child HIV Transmission (SMACHT) project, which was conducted in the Southern Province of Zambia from 2015 to 2020. Under SMACHT, CHEC significantly improved maternal/child HIVoutcomes [7] and achieved 90% linkage to ART and 91% viral suppression [8].We would like to discuss four key considerations that are relevant to the economic impacts: the models compared, the outcome selected, how retention is defined, and the ancillary benefits and savings that were not included.